A23L33/16

Composition comprising ethyl vanillin as effective ingredient for exhibiting effect of muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or sarcopenia suppression

The present invention relates to a composition comprising ethyl vanillin or a pharmaceutically acceptable salt thereof as an effective ingredient for preventing or treating muscle disease or for improving a muscle function. Having the capability of upregulating the expression of a protein associated with muscle protein synthesis and muscle mass increase in myocytes and downregulating at an mRNA level the expression of an enzyme involved in muscle protein degradation, ethyl vanillin can exhibit effects of muscle differentiation, muscle regeneration, and muscle strengthening through an increase in muscle mass against muscle diseases attributed to muscle function decrease, muscle consumption, or muscle degradation and can suppress sarcopenia. Thus, ethyl vanillin can be used for preventing or treating muscle diseases or for promoting muscle differentiation, muscle regeneration and muscle strengthening, muscle mass increase, or muscle generation or for improving muscle function.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MASTITIS

The present invention relates to compositions for use in treating or preventing mastitis, for example sub-clinical mastitis, in a subject. In particular, the invention relates to a diet and /or nutritional composition which are characterised by a low inflammatory potential for their use in in treating or preventing mastitis, in particular sub-clinical mastitis, in lactating women. The present invention also relates to a risk prediction tool for the occurrence of subclinical mastitis in lactating women, which is based on the inflammatory potential of their diets.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MASTITIS

The present invention relates to compositions for use in treating or preventing mastitis, for example sub-clinical mastitis, in a subject. In particular, the invention relates to a diet and /or nutritional composition which are characterised by a low inflammatory potential for their use in in treating or preventing mastitis, in particular sub-clinical mastitis, in lactating women. The present invention also relates to a risk prediction tool for the occurrence of subclinical mastitis in lactating women, which is based on the inflammatory potential of their diets.

DISPERSIBLE SPICE PELLETS

The present disclosure relates to a spice pellet comprising oligosaccharide in the range of 3-40% w/w of the total weight of the spice pellet, hydroxy propyl methyl cellulose (HPMC) in the range of 1-15% w/w of the total weight of the spice pellet, clarified butter in the range of 5-10% w/w of the total weight of the spice pellet, spice mixture in the range of 50-90% w/w of the total weight of the spice pellet. The present disclosure also relates to a method of making the spice pellet.

NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEINS
20230038577 · 2023-02-09 ·

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

Composition for enhancing skin elasticity or improving skin wrinkles comprising heptahydroxyflavan as an effective ingredient

Heptahydroxyflavan or a salt, isomer, hydrate or solvate thereof, which is an active ingredient of the present disclosure, can enhance skin elasticity and improve skin wrinkles by inhibiting the activity of MMP-1. In addition, the heptahydroxyflavan or a salt, isomer, hydrate or solvate thereof, which is an active ingredient of the present disclosure, can be used in various compositions such as cosmetics, health functional foods, etc. because it is safe with no cytotoxicity.

Pharmaceutical or food supplement preparation based on alpha-lactalbumin
11554162 · 2023-01-17 · ·

Pharmaceutical or food supplement preparation including alpha-lactalbumin and at least one short-chain fatty acid (SCFA) or a precursor or derivative thereof for use in the treatment of disorders of the central nervous system; the SCFA or its precursor or derivative may be contained in at least one first dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint and the alpha-lactalbumin in at least one second dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint, and said dosage units may be distinct units intended for simultaneous or separate administration or the preparation may consist of a pharmaceutical or food supplement composition comprising the at least one short-chain fatty acid or a precursor or derivative thereof and alpha-lactalbumin together with a carrier acceptable from the pharmaceutical or food standpoint.

Pharmaceutical or food supplement preparation based on alpha-lactalbumin
11554162 · 2023-01-17 · ·

Pharmaceutical or food supplement preparation including alpha-lactalbumin and at least one short-chain fatty acid (SCFA) or a precursor or derivative thereof for use in the treatment of disorders of the central nervous system; the SCFA or its precursor or derivative may be contained in at least one first dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint and the alpha-lactalbumin in at least one second dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint, and said dosage units may be distinct units intended for simultaneous or separate administration or the preparation may consist of a pharmaceutical or food supplement composition comprising the at least one short-chain fatty acid or a precursor or derivative thereof and alpha-lactalbumin together with a carrier acceptable from the pharmaceutical or food standpoint.

MICRONUTRIENT DELIVERY TO GUM POCKET
20230042036 · 2023-02-09 ·

The present invention includes composition and methods of delivering one or more nutrients to a subject comprising: delivering an effective amount of one or more nutrients into a gingival crevice wherein the amount is sufficient to supplement the diet of the subject for the nutrients.

MICRONUTRIENT DELIVERY TO GUM POCKET
20230042036 · 2023-02-09 ·

The present invention includes composition and methods of delivering one or more nutrients to a subject comprising: delivering an effective amount of one or more nutrients into a gingival crevice wherein the amount is sufficient to supplement the diet of the subject for the nutrients.